v3.21.1
Consolidated Statements of operations - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Revenue:      
Revenues $ 148,677 $ 124,784 $ 99,889
Expenses:      
Cost of revenue (excluding depreciation and amortization) 23,461 16,831 15,105
Payment processing expense 28,925 27,889 21,892
Sales and marketing 42,972 32,357 26,367
Research and development 22,622 18,623 14,349
General and administrative 40,460 30,458 20,076
Depreciation 9,770 8,753 7,552
Amortization 6,138 5,171 4,042
Total expenses 174,348 140,082 109,382
Operating loss (25,671) (15,298) (9,494)
Other income (expense), net 1 (1,023) (7)
Change in fair value of warrant liability 0 (3,307) (2,058)
Interest (expense) income, net (1,573) (2,445) (3,504)
Total other expense, net (1,572) (6,775) (5,568)
Loss before (provision for) benefit from income taxes (27,243) (22,073) (15,062)
(Provision for) benefit from income taxes (49) 1,780 0
Net loss (27,292) (20,293) (15,062)
Preferred stock dividends paid 0 (14,955) 0
Accretion of redeemable preferred stock 0 (56,175) (30,199)
Net loss attributable to common stockholders, basic and diluted $ (27,292) $ (91,423) $ (45,261)
Net loss per share attributable to common stockholders, basic and diluted (in USD per share) $ (0.69) $ (4.50) $ (24.53)
Weighted-average common shares outstanding, basic and diluted (in shares) 39,519,640 20,301,189 1,844,929
Subscription and related services      
Revenue:      
Revenues $ 69,042 $ 56,357 $ 43,928
Payment processing fees      
Revenue:      
Revenues 49,900 46,500 36,881
Life sciences      
Revenue:      
Revenues $ 29,735 $ 21,927 $ 19,080